{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-030020","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.310630+00:00","generated_at":"2026-05-25T23:32:24.016284+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"4DMT reports FY2024 net loss of $160.9M; cash $505M; Phase 3 programs on track","bullets":["Net loss of $160.9M in 2024 vs $100.8M in 2023; R&D expenses $141.3M (up 46% YoY).","Cash, cash equivalents and marketable securities of $505M as of Dec 31, 2024, funding operations into 2028.","Phase 3 4FRONT trials for 4D-150 in wet AMD to initiate March 2025 and Q3 2025; topline data expected H2 2027.","FDA aligned that a single Phase 3 trial is acceptable for BLA submission of 4D-150 in DME.","Pipeline focused on 4D-150 (wet AMD, DME) and 4D-710 (CF); paused other programs and terminated early-stage rare disease trials."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-030020","json":"https://secwatch.observer/filing/0000950170-25-030020.json","markdown":"https://secwatch.observer/filing/0000950170-25-030020.md","text":"https://secwatch.observer/filing/0000950170-25-030020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025030020/0000950170-25-030020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025030020/fdmt-20250228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T23:32:24.016284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}